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The polyphenol resveratrol (RV) was previously shown by
us to inhibit the angiotensin (Ang) II and epidermal
growth factor (EGF)-mediated phosphorylation of Akt in
vascular smooth muscle cells (VSMC) and fibroblasts. In
fibroblasts, RV was shown to activate the SH2 domain
containing phosphatase 2 (Shp2) leading to subsequent
dephosphorylation of Gab1 and an impaired recruitment
of the phosphoinositide 3-kinase (PI3K) to this adapter
protein at the EGF receptor. The present study aims (i) to
verify a role for Shp2 regarding the Akt inhibitory effect of
RV in VSMC, and (ii) to examine whether the RV effect on
Akt phosphorylation depends on a redox sensitive mech-
anism. An siRNA knock-down of Shp2 protein levels to
50% in VSMC still allowed RV to significantly inhibit
EGF- as well as Ang II-mediated Akt phosphorylation,
though less pronounced compared to control cells, nei-
ther verifying nor denying Shp2 as a potential target of RV
in VSMC. EGF and Ang II are reported to require reactive
oxygen species (ROS) to transduce their signal probably
by inactivating redox-sensitive phosphatases. Indeed,
intracellular ROS (measured by H2DCFDA) was signifi-
cantly induced by Ang II and EGF stimulation, and RV
pre-treatment kept intracellular ROS even below basal
control levels. Pre-treatment of VSMC with the antioxi-
dant N-acetyl cystein (NAC) and flavoprotein inhibitor
diphenylene iodonium (DPI) followed by stimulation
with Ang II and EGF, respectively, showed that NAC and
DPI were able to inhibit Ang II-mediated Akt phosphor-
ylation. However, they failed to inhibit phosphorylation
of Akt upon stimulation with EGF. This confirms that Ang
II signalling requires ROS to transactivate the EGF recep-
tor, whereas the signalling downstream of the EGF recep-
tor towards Akt seems to occur largely independently
from ROS. Since RV was shown to interfere downstream
of the EGF receptor with the PI3K/Akt pathway, we con-
clude that Akt inhibition by RV most likely occurs redox-
independently. Thus, if Shp2 is a target for RV, it seems
not to be redox-regulated by RV.
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